[{"edinetCode":"E00971","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":352.0,"averageTemporaryStaff":56.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":14038000.0,"sharesOwendPercent":0.6226,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":1457.52,"equityRatio":0.92,"cashAndCashEquivalents":14731248000.0,"assets":35478419000.0,"currentAssets":28725511000.0,"fixedAsset":6752908000.0,"tangibleFixedAssets":4177108000.0,"intangibleFixedAssets":98883000.0,"investmentAndOtherAssets":2476916000.0,"liabilities":2836878000.0,"currentLiabilities":2329833000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":507044000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32641541000.0,"capitalStock":32520037000.0,"capital":4449844000.0,"capitalSurplus":5378511000.0,"accumulatedEarnings":22791052000.0,"treasuryStock":-99371000.0,"valuationAndConversionAdjustments":121504000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":12825171000.0,"costOfSales":6441622000.0,"grossProfit":6383548000.0,"sgaExpenses":4685749000.0,"salaryAndBenefit":1021623000.0,"depreciationAndSGA":null,"RDExpenses":866081000.0,"operatingIncome":1697799000.0,"nonOperatingIncome":1024397000.0,"nonOperatingExpenses":882869000.0,"interestExpense":37000.0,"ordinaryProfit":1839327000.0,"extraordinaryGain":800477000.0,"extraordinaryLoss":55856000.0,"incomeBeforeTax":2583948000.0,"incomeTaxes":681050000.0,"netIncome":1902898000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1902898000.0,"comprehensiveIncome":2652967000.0,"eps":84.97,"dilutedEps":null,"dividendPerShare":null,"per":16.3,"roe":0.06,"cashFlowFromOperatingActivities":1095997000.0,"depreciationAndCashflowFromOperatingActivities":405039000.0,"cashFlowFromInvestingActivities":11694098000.0,"cashFlowFromFinancialActivities":-928506000.0,"changesInCashAndCashEquivalents":11861588000.0,"列1":"asr","submitDate":"2017\/6\/23","stockCode":4550,"accountingYear":"第85期（自　平成28年４月１日　至　平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":316.0,"averageTemporaryStaff":50.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":14010000.0,"sharesOwendPercent":0.6256,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":1472.4,"equityRatio":0.92,"cashAndCashEquivalents":15029000000.0,"assets":35860000000.0,"currentAssets":29080000000.0,"fixedAsset":6780000000.0,"tangibleFixedAssets":3893000000.0,"intangibleFixedAssets":111000000.0,"investmentAndOtherAssets":2775000000.0,"liabilities":2885000000.0,"currentLiabilities":2380000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":505000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32974000000.0,"capitalStock":32799000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":23071000000.0,"treasuryStock":-99000000.0,"valuationAndConversionAdjustments":174000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":12329000000.0,"costOfSales":6476000000.0,"grossProfit":5853000000.0,"sgaExpenses":4425000000.0,"salaryAndBenefit":966000000.0,"depreciationAndSGA":null,"RDExpenses":772000000.0,"operatingIncome":1427000000.0,"nonOperatingIncome":112000000.0,"nonOperatingExpenses":4000000.0,"interestExpense":0.0,"ordinaryProfit":1535000000.0,"extraordinaryGain":161000000.0,"extraordinaryLoss":5000000.0,"incomeBeforeTax":1691000000.0,"incomeTaxes":515000000.0,"netIncome":1175000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1175000000.0,"comprehensiveIncome":1229000000.0,"eps":52.5,"dilutedEps":null,"dividendPerShare":null,"per":26.2,"roe":0.036,"cashFlowFromOperatingActivities":865000000.0,"depreciationAndCashflowFromOperatingActivities":388000000.0,"cashFlowFromInvestingActivities":362000000.0,"cashFlowFromFinancialActivities":-929000000.0,"changesInCashAndCashEquivalents":298000000.0,"列1":"asr","submitDate":"2018\/6\/22","stockCode":4550,"accountingYear":"第86期（自　平成29年４月１日　至　平成30年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":316.0,"averageTemporaryStaff":43.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":14102000.0,"sharesOwendPercent":0.6297,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":1465.88,"equityRatio":0.914,"cashAndCashEquivalents":4935000000.0,"assets":35901000000.0,"currentAssets":29406000000.0,"fixedAsset":6494000000.0,"tangibleFixedAssets":3848000000.0,"intangibleFixedAssets":109000000.0,"investmentAndOtherAssets":2537000000.0,"liabilities":3073000000.0,"currentLiabilities":2481000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":592000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32827000000.0,"capitalStock":32688000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22960000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":139000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":12549000000.0,"costOfSales":6791000000.0,"grossProfit":5758000000.0,"sgaExpenses":4445000000.0,"salaryAndBenefit":973000000.0,"depreciationAndSGA":null,"RDExpenses":640000000.0,"operatingIncome":1312000000.0,"nonOperatingIncome":89000000.0,"nonOperatingExpenses":17000000.0,"interestExpense":0.0,"ordinaryProfit":1385000000.0,"extraordinaryGain":null,"extraordinaryLoss":2000000.0,"incomeBeforeTax":1382000000.0,"incomeTaxes":597000000.0,"netIncome":784000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":784000000.0,"comprehensiveIncome":749000000.0,"eps":35.05,"dilutedEps":null,"dividendPerShare":null,"per":33.2,"roe":0.024,"cashFlowFromOperatingActivities":1364000000.0,"depreciationAndCashflowFromOperatingActivities":380000000.0,"cashFlowFromInvestingActivities":-10527000000.0,"cashFlowFromFinancialActivities":-930000000.0,"changesInCashAndCashEquivalents":-10094000000.0,"列1":"asr","submitDate":"2019\/6\/21","stockCode":4550,"accountingYear":"第87期（自　2018年４月１日　至　2019年３月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.925,"cashAndCashEquivalents":null,"assets":34910000000.0,"currentAssets":28740000000.0,"fixedAsset":6170000000.0,"tangibleFixedAssets":3790000000.0,"intangibleFixedAssets":100000000.0,"investmentAndOtherAssets":2279000000.0,"liabilities":2603000000.0,"currentLiabilities":2031000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":571000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32306000000.0,"capitalStock":32187000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22459000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":118000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":2835000000.0,"costOfSales":1571000000.0,"grossProfit":1263000000.0,"sgaExpenses":1095000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":168000000.0,"nonOperatingIncome":25000000.0,"nonOperatingExpenses":23000000.0,"interestExpense":0.0,"ordinaryProfit":170000000.0,"extraordinaryGain":11000000.0,"extraordinaryLoss":133000000.0,"incomeBeforeTax":48000000.0,"incomeTaxes":50000000.0,"netIncome":-1000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1000000.0,"comprehensiveIncome":-22000000.0,"eps":-0.06,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4550,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":14119000.0,"sharesOwendPercent":0.6305,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.92,"cashAndCashEquivalents":10597000000.0,"assets":35451000000.0,"currentAssets":29311000000.0,"fixedAsset":6139000000.0,"tangibleFixedAssets":3709000000.0,"intangibleFixedAssets":93000000.0,"investmentAndOtherAssets":2336000000.0,"liabilities":2818000000.0,"currentLiabilities":2267000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":551000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32633000000.0,"capitalStock":32502000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22774000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":130000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":6260000000.0,"costOfSales":3437000000.0,"grossProfit":2823000000.0,"sgaExpenses":2255000000.0,"salaryAndBenefit":502000000.0,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":567000000.0,"nonOperatingIncome":51000000.0,"nonOperatingExpenses":43000000.0,"interestExpense":0.0,"ordinaryProfit":575000000.0,"extraordinaryGain":16000000.0,"extraordinaryLoss":134000000.0,"incomeBeforeTax":457000000.0,"incomeTaxes":144000000.0,"netIncome":313000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":313000000.0,"comprehensiveIncome":304000000.0,"eps":13.98,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":494000000.0,"depreciationAndCashflowFromOperatingActivities":173000000.0,"cashFlowFromInvestingActivities":5632000000.0,"cashFlowFromFinancialActivities":-465000000.0,"changesInCashAndCashEquivalents":5662000000.0,"列1":"q2r","submitDate":"2019\/11\/8","stockCode":4550,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.92,"cashAndCashEquivalents":null,"assets":35232000000.0,"currentAssets":28185000000.0,"fixedAsset":7046000000.0,"tangibleFixedAssets":5016000000.0,"intangibleFixedAssets":96000000.0,"investmentAndOtherAssets":1933000000.0,"liabilities":2831000000.0,"currentLiabilities":2279000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":551000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32401000000.0,"capitalStock":32235000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22507000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":165000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":9318000000.0,"costOfSales":5169000000.0,"grossProfit":4149000000.0,"sgaExpenses":3378000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":770000000.0,"nonOperatingIncome":93000000.0,"nonOperatingExpenses":59000000.0,"interestExpense":0.0,"ordinaryProfit":804000000.0,"extraordinaryGain":16000000.0,"extraordinaryLoss":134000000.0,"incomeBeforeTax":686000000.0,"incomeTaxes":192000000.0,"netIncome":493000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":493000000.0,"comprehensiveIncome":520000000.0,"eps":22.05,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/7","stockCode":4550,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":306.0,"averageTemporaryStaff":44.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":14265000.0,"sharesOwendPercent":0.637,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":1436.82,"equityRatio":0.914,"cashAndCashEquivalents":3558000000.0,"assets":35203000000.0,"currentAssets":28503000000.0,"fixedAsset":6700000000.0,"tangibleFixedAssets":4962000000.0,"intangibleFixedAssets":101000000.0,"investmentAndOtherAssets":1636000000.0,"liabilities":3027000000.0,"currentLiabilities":2592000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":434000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32176000000.0,"capitalStock":32143000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22415000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":33000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":12773000000.0,"costOfSales":7047000000.0,"grossProfit":5725000000.0,"sgaExpenses":4580000000.0,"salaryAndBenefit":998000000.0,"depreciationAndSGA":null,"RDExpenses":695000000.0,"operatingIncome":1144000000.0,"nonOperatingIncome":115000000.0,"nonOperatingExpenses":268000000.0,"interestExpense":0.0,"ordinaryProfit":991000000.0,"extraordinaryGain":16000000.0,"extraordinaryLoss":364000000.0,"incomeBeforeTax":642000000.0,"incomeTaxes":240000000.0,"netIncome":401000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":401000000.0,"comprehensiveIncome":295000000.0,"eps":17.95,"dilutedEps":null,"dividendPerShare":null,"per":68.4,"roe":0.012,"cashFlowFromOperatingActivities":1494000000.0,"depreciationAndCashflowFromOperatingActivities":365000000.0,"cashFlowFromInvestingActivities":-1940000000.0,"cashFlowFromFinancialActivities":-931000000.0,"changesInCashAndCashEquivalents":-1376000000.0,"列1":"asr","submitDate":"2020\/6\/19","stockCode":4550,"accountingYear":"第88期（自　2019年４月１日　至　2020年３月31日）","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.936,"cashAndCashEquivalents":null,"assets":34244000000.0,"currentAssets":28607000000.0,"fixedAsset":5637000000.0,"tangibleFixedAssets":3420000000.0,"intangibleFixedAssets":92000000.0,"investmentAndOtherAssets":2123000000.0,"liabilities":2182000000.0,"currentLiabilities":1803000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":379000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32061000000.0,"capitalStock":31947000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22219000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":114000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":2129000000.0,"costOfSales":1267000000.0,"grossProfit":862000000.0,"sgaExpenses":822000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":40000000.0,"nonOperatingIncome":51000000.0,"nonOperatingExpenses":21000000.0,"interestExpense":0.0,"ordinaryProfit":70000000.0,"extraordinaryGain":null,"extraordinaryLoss":1000000.0,"incomeBeforeTax":68000000.0,"incomeTaxes":29000000.0,"netIncome":39000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":39000000.0,"comprehensiveIncome":120000000.0,"eps":1.76,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/7","stockCode":4550,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":13993000.0,"sharesOwendPercent":0.6249,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.93,"cashAndCashEquivalents":9168000000.0,"assets":34728000000.0,"currentAssets":29234000000.0,"fixedAsset":5494000000.0,"tangibleFixedAssets":3383000000.0,"intangibleFixedAssets":83000000.0,"investmentAndOtherAssets":2027000000.0,"liabilities":2446000000.0,"currentLiabilities":2069000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":377000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32282000000.0,"capitalStock":32168000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22440000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":113000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":5139000000.0,"costOfSales":3183000000.0,"grossProfit":1956000000.0,"sgaExpenses":1655000000.0,"salaryAndBenefit":389000000.0,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":300000000.0,"nonOperatingIncome":133000000.0,"nonOperatingExpenses":36000000.0,"interestExpense":0.0,"ordinaryProfit":397000000.0,"extraordinaryGain":null,"extraordinaryLoss":12000000.0,"incomeBeforeTax":385000000.0,"incomeTaxes":124000000.0,"netIncome":260000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":260000000.0,"comprehensiveIncome":340000000.0,"eps":11.64,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":105000000.0,"depreciationAndCashflowFromOperatingActivities":142000000.0,"cashFlowFromInvestingActivities":5726000000.0,"cashFlowFromFinancialActivities":-242000000.0,"changesInCashAndCashEquivalents":5589000000.0,"列1":"q2r","submitDate":"2020\/11\/6","stockCode":4550,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.912,"cashAndCashEquivalents":null,"assets":35350000000.0,"currentAssets":30010000000.0,"fixedAsset":5339000000.0,"tangibleFixedAssets":3322000000.0,"intangibleFixedAssets":73000000.0,"investmentAndOtherAssets":1943000000.0,"liabilities":3123000000.0,"currentLiabilities":2746000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":376000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32227000000.0,"capitalStock":32138000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22410000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":88000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":8602000000.0,"costOfSales":5568000000.0,"grossProfit":3034000000.0,"sgaExpenses":2496000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":537000000.0,"nonOperatingIncome":170000000.0,"nonOperatingExpenses":39000000.0,"interestExpense":0.0,"ordinaryProfit":667000000.0,"extraordinaryGain":null,"extraordinaryLoss":12000000.0,"incomeBeforeTax":655000000.0,"incomeTaxes":200000000.0,"netIncome":454000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":454000000.0,"comprehensiveIncome":510000000.0,"eps":20.32,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/10","stockCode":4550,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":250.0,"averageTemporaryStaff":36.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":14285000.0,"sharesOwendPercent":0.638,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":1450.4,"equityRatio":0.907,"cashAndCashEquivalents":4527000000.0,"assets":35813000000.0,"currentAssets":30400000000.0,"fixedAsset":5413000000.0,"tangibleFixedAssets":3274000000.0,"intangibleFixedAssets":77000000.0,"investmentAndOtherAssets":2061000000.0,"liabilities":3333000000.0,"currentLiabilities":2948000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":384000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32480000000.0,"capitalStock":32332000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22604000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":148000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":12384000000.0,"costOfSales":8186000000.0,"grossProfit":4197000000.0,"sgaExpenses":3404000000.0,"salaryAndBenefit":786000000.0,"depreciationAndSGA":null,"RDExpenses":643000000.0,"operatingIncome":793000000.0,"nonOperatingIncome":207000000.0,"nonOperatingExpenses":55000000.0,"interestExpense":0.0,"ordinaryProfit":944000000.0,"extraordinaryGain":null,"extraordinaryLoss":12000000.0,"incomeBeforeTax":932000000.0,"incomeTaxes":284000000.0,"netIncome":648000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":648000000.0,"comprehensiveIncome":763000000.0,"eps":28.95,"dilutedEps":null,"dividendPerShare":null,"per":34.4,"roe":0.02,"cashFlowFromOperatingActivities":485000000.0,"depreciationAndCashflowFromOperatingActivities":286000000.0,"cashFlowFromInvestingActivities":938000000.0,"cashFlowFromFinancialActivities":-476000000.0,"changesInCashAndCashEquivalents":947000000.0,"列1":"asr","submitDate":"2021\/6\/22","stockCode":4550,"accountingYear":"第89期（自　2020年４月１日　至　2021年３月31日）","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.904,"cashAndCashEquivalents":null,"assets":35860000000.0,"currentAssets":30532000000.0,"fixedAsset":5328000000.0,"tangibleFixedAssets":3232000000.0,"intangibleFixedAssets":69000000.0,"investmentAndOtherAssets":2026000000.0,"liabilities":3435000000.0,"currentLiabilities":3051000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":383000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32425000000.0,"capitalStock":32265000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22537000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":160000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":4183000000.0,"costOfSales":2867000000.0,"grossProfit":1316000000.0,"sgaExpenses":823000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":492000000.0,"nonOperatingIncome":46000000.0,"nonOperatingExpenses":0.0,"interestExpense":0.0,"ordinaryProfit":539000000.0,"extraordinaryGain":8000000.0,"extraordinaryLoss":0.0,"incomeBeforeTax":547000000.0,"incomeTaxes":158000000.0,"netIncome":389000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":389000000.0,"comprehensiveIncome":400000000.0,"eps":17.37,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/6","stockCode":4550,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":14579000.0,"sharesOwendPercent":0.651,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.892,"cashAndCashEquivalents":4938000000.0,"assets":36716000000.0,"currentAssets":31581000000.0,"fixedAsset":5135000000.0,"tangibleFixedAssets":3201000000.0,"intangibleFixedAssets":64000000.0,"investmentAndOtherAssets":1868000000.0,"liabilities":3972000000.0,"currentLiabilities":3589000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":382000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32744000000.0,"capitalStock":32531000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22804000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":212000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":8366000000.0,"costOfSales":5701000000.0,"grossProfit":2664000000.0,"sgaExpenses":1807000000.0,"salaryAndBenefit":403000000.0,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":857000000.0,"nonOperatingIncome":73000000.0,"nonOperatingExpenses":1000000.0,"interestExpense":0.0,"ordinaryProfit":928000000.0,"extraordinaryGain":8000000.0,"extraordinaryLoss":0.0,"incomeBeforeTax":936000000.0,"incomeTaxes":281000000.0,"netIncome":655000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":655000000.0,"comprehensiveIncome":719000000.0,"eps":29.28,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":545000000.0,"depreciationAndCashflowFromOperatingActivities":114000000.0,"cashFlowFromInvestingActivities":313000000.0,"cashFlowFromFinancialActivities":-448000000.0,"changesInCashAndCashEquivalents":411000000.0,"列1":"q2r","submitDate":"2021\/11\/5","stockCode":4550,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00971","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.899,"cashAndCashEquivalents":null,"assets":35983000000.0,"currentAssets":30980000000.0,"fixedAsset":5003000000.0,"tangibleFixedAssets":3171000000.0,"intangibleFixedAssets":62000000.0,"investmentAndOtherAssets":1769000000.0,"liabilities":3621000000.0,"currentLiabilities":3221000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":399000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":32362000000.0,"capitalStock":32201000000.0,"capital":4449000000.0,"capitalSurplus":5378000000.0,"accumulatedEarnings":22473000000.0,"treasuryStock":-100000000.0,"valuationAndConversionAdjustments":160000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":11609000000.0,"costOfSales":7751000000.0,"grossProfit":3857000000.0,"sgaExpenses":2647000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1209000000.0,"nonOperatingIncome":97000000.0,"nonOperatingExpenses":99000000.0,"interestExpense":0.0,"ordinaryProfit":1208000000.0,"extraordinaryGain":58000000.0,"extraordinaryLoss":0.0,"incomeBeforeTax":1265000000.0,"incomeTaxes":380000000.0,"netIncome":885000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":885000000.0,"comprehensiveIncome":897000000.0,"eps":39.53,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/4","stockCode":4550,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00971","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4449,"settlementDate":"2022\/3\/31","submitterName":"日水製薬株式会社","submitterNameEnglish":"Nissui Pharmaceutical  Co.,  Ltd.","submitterNameKana":"ニッスイセイヤクカブシキガイシャ","location":"台東区上野三丁目２４番６号","industory":"医薬品","corporateNumber":9010000000000.0}]